Follow us as we translate our deep expertise in structure-based drug discovery into novel, selective therapeutics that enable durable responses for patients with cancer.

Patient Impact Drives Solutions
James R. Porter, Ph. D.
James R. Porter, PhD
Chief Executive Officer
Jim shares more about Nuvalent’s foundation and approach – to provide new impactful therapies for patients living with cancer.